Pharmacist New Drugs | Pain Management Podcast 30m

Patients with fibromyalgia have waited more than a decade for a new therapeutic option, and a recent regulatory approval signals a shift for these patients. This episode reviews the clinical trial data, mechanism of action, dosing considerations, and pharmacist-relevant monitoring for the newly approved sublingual formulation of cyclobenzaprine HCl. You will gain practical insights to inform patient education, therapy optimization, and interdisciplinary collaboration in fibromyalgia care.

Learning Objectives

Upon successful completion of this course, pharmacists should be able to:
1. Describe the mechanism of action and key clinical trial outcomes associated with the newly approved prescription medication for fibromyalgia.
2. Identify pharmacist responsibilities for dosing, monitoring adverse effects, and patient counseling when supporting the use of this new fibromyalgia therapy. 

Faculty

Rachel Maynard, PharmD

GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

Disclosures:

Rachel Maynard has no relevant financial relationships with ineligible companies to disclose.

Amanda (Mandy) Mullins, PharmD, BCPS

Clinical Pharmacist Practitioner
Veterans Affairs

Disclosures:

Amanda (Mandy) Mullins has no relevant financial relationships with ineligible companies to disclose.

Course Details